(Q37992829)

26 August 2017

title

The adjuvant treatment of HER2-positive breast cancer (English)

1 reference

26 August 2017

1 reference

Danijela Jelovac

1

1 reference

26 August 2017

Antonio C Wolff

series ordinal

2

1 reference

26 August 2017

publication date

1 June 2012

1 reference

Current Treatment Options in Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

13

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

230-239

1 reference

Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Effect of screening and adjuvant therapy on mortality from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0186-4

TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer

21 January 2018

1 reference

12 December 2020

Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer

1 reference

12 December 2020

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

12 December 2020

Heart of darkness: the downside of trastuzumab

1 reference

12 December 2020

Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer

1 reference

12 December 2020

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

12 December 2020

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

1 reference

12 December 2020

10.1007/S11864-012-0186-4

Identifiers

DOI

1 reference

26 August 2017

1 reference